People · Operator
Named in public records as an officer, director or promoter · active 2013–2013 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Stem Cell Therapeutics Corp | — | Biotechnology | Series B | $30.3M | $1.2B | 2013 |
James Michael DeMesa at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Michael DeMesa on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Niclas Stiernholm | 1 | 2 |
| Robert Uger | 1 | 2 |
| Penka Petrova | 1 | 2 |
| James Todd Parsons | 1 | 1 |
| Ronald Dean Peterson | 1 | 1 |
| Michael G. Moore | 1 | 1 |
| Henry G. Friesen | 1 | 1 |
| David Geoffrey Peter Allan | 1 | 1 |
| Calvin Ralph Stiller | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.